Literature DB >> 36169725

Feasibility and outcome of spleen and vessel preserving total pancreatectomy (SVPTP) in pancreatic malignancies - a retrospective cohort study.

Christian Beltzer1,2, Elio Jovine3, Konstantin-Viktor Hesch1, Derna Stifini1, Laura Mastrangelo3, Marco Huth1,4, Alfred Königsrainer1, Silvio Nadalin5.   

Abstract

INTRODUCTION: Total pancreatectomy (TP) is most commonly performed to avoid postoperative pancreatic fistula (POPF) in patients with high-risk pancreas or to achieve tumor-free resection margins. As part of TP, a simultaneous splenectomy is usually performed primarily for the reason of oncologic radicality. However, the benefit of a simultaneous splenectomy remains unclear. Likewise, the technical feasibility as well as the safety of spleen and vessel preserving total pancreatectomy in pancreatic malignancies has hardly been evaluated. Thus, the aims of the study were to evaluate the feasibility as well as the results of spleen and vessel preserving total pancreatectomy (SVPTP).
MATERIAL AND METHODS: Patient characteristics, technical feasibility, perioperative data, morbidity, and mortality as well as histopathological results after SVPTP, mainly for pancreatic malignancies, from patient cohorts of two European high-volume-centers for pancreatic surgery were retrospectively analyzed. Mortality was set as the primary outcome and morbidity (complications according to Clavien-Dindo) as the secondary outcome.
RESULTS: A SVPTP was performed in 92 patients, predominantly with pancreatic adenocarcinoma (78.3%). In all cases, the splenic vessels could be preserved. In 59 patients, the decision to total pancreatectomy was made intraoperatively. Among these, the most common reason for total pancreatectomy was risk of POPF (78%). The 30-day mortality was 2.2%. Major complications (≥ IIIb according to Clavien-Dindo) occurred in 18.5% within 30 postoperative days. There were no complications directly related to the spleen and vascular preservation procedure. A tumor-negative resection margin was achieved in 71.8%.
CONCLUSION: We could demonstrate the technical feasibility and safety of SVPTP even in patients mainly with pancreatic malignancies. In addition to potential immunologic and oncologic advantages, we believe a major benefit of this procedure is preservation of gastric venous outflow. We consider SVPTP to be indicated in patients at high risk for POPF, in patients with multilocular IPMN, and in cases for extended intrapancreatic cancers.
© 2022. The Author(s).

Entities:  

Keywords:  Pancreatoduodenectomy; Postoperative pancreatic fistula; Spleen preservation; Splenectomy; Total pancreatectomy; Vessel preservation

Year:  2022        PMID: 36169725     DOI: 10.1007/s00423-022-02690-7

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   2.895


  32 in total

1.  Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Ducreux; A Sa Cuhna; C Caramella; A Hollebecque; P Burtin; D Goéré; T Seufferlein; K Haustermans; J L Van Laethem; T Conroy; D Arnold
Journal:  Ann Oncol       Date:  2015-09       Impact factor: 32.976

2.  Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Group of Pancreatobiliary Surgery in Japan.

Authors:  Sohei Satoi; Yoshiaki Murakami; Fuyuhiko Motoi; Masayuki Sho; Ippei Matsumoto; Kenichiro Uemura; Manabu Kawai; Masanao Kurata; Hiroaki Yanagimoto; Tomohisa Yamamoto; Masamichi Mizuma; Michiaki Unno; Shoichi Kinoshita; Takahiro Akahori; Makoto Shinzeki; Takumi Fukumoto; Yasushi Hashimoto; Seiko Hirono; Hiroki Yamaue; Goro Honda; Masanori Kwon
Journal:  Pancreas       Date:  2016-08       Impact factor: 3.327

3.  Sinistral portal hypertension after pancreaticoduodenectomy with splenic vein ligation.

Authors:  Y Ono; K Matsueda; R Koga; Y Takahashi; J Arita; M Takahashi; Y Inoue; T Unno; A Saiura
Journal:  Br J Surg       Date:  2014-12-18       Impact factor: 6.939

4.  Splenectomy and increased subsequent cancer risk: a nationwide population-based cohort study.

Authors:  Li-Min Sun; Hsuan-Ju Chen; Long-Bin Jeng; Tsai-Chung Li; Shih-Chi Wu; Chia-Hung Kao
Journal:  Am J Surg       Date:  2015-04-23       Impact factor: 2.565

Review 5.  Pancreatic Cancer: A Review.

Authors:  Wungki Park; Akhil Chawla; Eileen M O'Reilly
Journal:  JAMA       Date:  2021-09-07       Impact factor: 157.335

6.  A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy.

Authors:  Mark P Callery; Wande B Pratt; Tara S Kent; Elliot L Chaikof; Charles M Vollmer
Journal:  J Am Coll Surg       Date:  2012-11-02       Impact factor: 6.113

Review 7.  Are There Indications for Total Pancreatectomy in 2016?

Authors:  Åke Andrén-Sandberg; Christoph Ansorge; Thakur Deen Yadav
Journal:  Dig Surg       Date:  2016-05-25       Impact factor: 2.588

8.  Clinical comparison of distal pancreatectomy with or without splenectomy: a meta-analysis.

Authors:  Zhigang He; Daohai Qian; Jie Hua; Jian Gong; Shengping Lin; Zhenshun Song
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240

9.  Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model.

Authors:  Ho Kyoung Hwang; Takashi Murakami; Tasuku Kiyuna; Se Hoon Kim; Sung Hwan Lee; Chang Moo Kang; Robert M Hoffman; Michael Bouvet
Journal:  Oncotarget       Date:  2017-09-28

Review 10.  Total pancreatectomy and pancreatic fistula: friend or foe?

Authors:  Roberto Salvia; Gabriella Lionetto; Giampaolo Perri; Giuseppe Malleo; Giovanni Marchegiani
Journal:  Updates Surg       Date:  2021-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.